Verastem Oncology Reports Positive RAMP 201 Clinical Data

Verastem reported RAMP 201 molecular profiling and an external control arm analysis showing higher ORR and PFS for avutometinib + defactinib vs conventional care in recurrent LGSOC. The data included KRAS-mutated and wild-type subgroups.